Abstract
Background: Paclitaxel-carboplatin chemotherapy can cause hema-tological disorders. This regiment's hematological side effects include anemia, neutropenia, and thrombocytopenia. Data showed this regiment side effect occurs with grade iii/iv toxicity anemia, grade III/IV anemia by 41%, neutropenia (78%), and thrombocytopenia (41%). This hema-tological disorder occurs in bone marrow-producing areas due to chemotherapy. Each hematological disorder requires separate interven-tion.Case Presentation: A 54-year-old woman was diagnosed with a progressive disease of left lung adenocarcinoma (Exon 21 mutation) with TKI and received paclitaxel-carboplatin chemotherapy. The patient experienced side effects of anemia, neutropenia, and thrombocytopenia. Anemia was treated with PRC transfusion, neutropenia corrected with Filgrastim, and thrombocytopenia with platelet transfusion. Chemo-therapy was discontinued after five cycles because the Thrombo-cytopenia condition did not improve.Conclusion: Hematological parameters are essential in preparing for lung cancer chemotherapy. Uncorrectable hematological disorders lead to discontinuation of chemotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: MAGNA MEDICA Berkala Ilmiah Kedokteran dan Kesehatan
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.